Michael Friis

Head of Equities

Latest content

ShowingAll content types

Pharma Equity Group (Investment case): Partnerships key to de-risk the investment case

Research 08.04.2026 klo 14.47 by Philip Coombes, Michael Friis

Pharma Equity Group

ExpreS2ion: Final terms set on rights issue of SEK 53 million

Analyst Comment 07.04.2026 klo 11.58 by Michael Friis

ExpreS2ion Biotech Holding

BioPorto (Investment Case): Executing on the Forward strategy with adult pre-submission filed in Q1 2026

Research 01.04.2026 klo 17.37 by Philip Coombes, Michael Friis

BioPorto

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account

Stock market's most popular morning newsletter

Analyst comments and recommendations

Stock comparison tool

PREMIUM account

All company reports and content

Premium tools (e.g. insider transactions & stock screener)

Model portfolio

Create account

WindowMaster (Investment case): High earnings growth set to return in 2026

Research 31.03.2026 klo 09.30 by Michael Friis, Victor Skriver

WindowMaster International

GreenMobility (Investment case): Proven profitability, levers for the next growth phase identified

Research 26.03.2026 klo 14.45 by Michael Friis, Victor Skriver

GreenMobility

GreenMobility: Recording of 2025 annual report presentation

Analyst Comment 25.03.2026 klo 16.01 by Michael Friis

GreenMobility

ExpreS2ion: ES2B-C001 clears another hurdle: consistent immune responses and green light to escalate

Analyst Comment 25.03.2026 klo 12.17 by Michael Friis

ExpreS2ion Biotech Holding

Wirtek (Investment case): Well-positioned to increase profitability

Research 20.03.2026 klo 15.30 by Michael Friis, Victor Skriver

Wirtek

Wirtek: Recording of FY 2025 results presentation

Analyst Comment 19.03.2026 klo 16.57 by Michael Friis